Skinvisible Subsidiary Kintari Has Successful Launch

Kintari Officially in Business

skvi-shadow-logo

LAS VEGAS, NV / Skinvisible Inc., (OTCQB: SKVI) through its wholly owned subsidiary Kintari International Inc., marketer of patented “Youth Renewed” skin care products, is pleased to announce the successful official launch of its network marketing company.

B“We are very pleased to announce that our January 15th official launch of Kintari in the USA was very exciting for us and the new distributors that attended from across the US,” said Mr. Terry Howlett, President of Kintari.

The Kintari product portfolio consists of “Youth Renewed” (YR) anti-aging products to help fight the signs of aging. The Kintari YR product line includes a rejuvenating day cream and a renewing night cream. These products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients are powered by our patented Invisicare(R) skin delivery technology, providing consumers with unique, effective skincare benefits which cannot be duplicated and our Kintari distributors with products that no other company can offer. Kintari products are truly one of a kind.

D“New distributor sign ups and sales for the two week period ending January 30 were above expectations and the response to our products has been outstanding said Mr. Rob Barnes, Director of Sales. Based on the success of our first month, we anticipate continued growth in both new distributors and sales over the next months. This growth will be generated by new distributors from across the USA, new product launches in 2015 and the launch of Kintari Canada in the second quarter of 2015.”

Skinvisible Inc., a science-based research and development company with a patented skin delivery technology called Invisicare(R), the foundation to every topical prescription (Rx), over-the-counter (OTC) and cosmeceutical product developed by Skinvisible. Skinvisible continues to build its worldwide patent portfolio while seeking licensees for its prescription line of dermatology focused products, while Kintari focuses exclusively on the marketing of OTC and cosmeceutical products powered by Invisicare. Presently the company has over fifteen patents worldwide and a portfolio of over forty products ready to be licensed or introduced to the marketplace.

 

About Skinvisible Pharmaceuticals, Inc.

 

Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. In addition, Skinvisible’s wholly-owned subsidiary Kintari will commercialize its cosmeceutical and OTC product line globally through network marketing. www.skinvisible.com www.invisicare.com www.kintari.com.

Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10k for the quarter ending September 30, 2014).

 

IR Contact:

John Pentony, Investor Relations

Ph: 972-292-8930

Email: [email protected]

Corporate Contact:

Doreen McMorran, Skinvisible Inc. & Kintari USA Inc.

Phone: 702-433-7154

Email: [email protected]

 

 

 

John Pentony now represents Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock. John Pentony has signed a contract to as investor relations for Skinvisible, and will be paid up to eleven thousand dollars during the next twelve months should the contract go for twelve months as expected.